Andy Porter - 17 Dec 2021 Form 3 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Title: Executive Vice President, Chief People Experience Officer Exhibit 24 - Power of Attorney
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
17 Dec 2021
Net transactions value
$0
Form type
3
Filing time
27 Dec 2021, 17:36:40 UTC
Next filing
27 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RLAY Common Stock 23,407 17 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RLAY Stock Option (Right to Buy) 17 Dec 2021 Common Stock 143,926 $5.04 Direct F2
holding RLAY Stock Option (Right to Buy) 17 Dec 2021 Common Stock 13,861 $5.22 Direct F3
holding RLAY Stock Option (Right to Buy) 17 Dec 2021 Common Stock 47,522 $5.22 Direct F4
holding RLAY Stock Option (Right to Buy) 17 Dec 2021 Common Stock 28,000 $34.25 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 12,250 restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs commenced vesting in 16 equal quarterly installments following the grant date of March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date.
F2 24,239 shares underlying this option have vested and the remainder shall vest in equal quarterly installments from January 21, 2022 to October 21, 2023, subject to the reporting person's continued service with the Issuer through each vesting date.
F3 2,970 shares underlying this option have vested and the remainder shall vest in equal quarterly installments from December 23, 2021 to June 23, 2024, subject to the reporting person's continued service with the Issuer through each vesting date.
F4 11,880 shares underlying this option have vested and the remainder shall vest in equal quarterly installments from March 11, 2022 to December 11, 2024, subject to the reporting person's continued service with the Issuer through each vesting date.
F5 3,500 shares underlying this option have vested and the remainder shall vest in equal quarterly installments from December 26, 2021 to March 26, 2025, subject to the reporting person's continued service with the Issuer through each vesting date.

Remarks:

Title: Executive Vice President, Chief People Experience Officer Exhibit 24 - Power of Attorney